Search clinical trials for: IBI130

Total 321 results

Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery

Acral Melanoma That Has Been Removed by Surgery

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPC

NPC

China
Peking University
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer

Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)

DLBCL

China
Tongji Hospital
Wuhan University; Henan Cancer Hospital; Qilu Hospital of Shandong University; Hubei... and other collaborators

Recruiting

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (INOVA)

Ovarian Clear Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicentre,Study of IBI133 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumours

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)

NSCLC (Non-small-cell Lung Cancer)

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in Neoadjuvant and Adjuvant Therapy of Radically Resectable Non-small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Healthy Subjects

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI334 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Unknown

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment

Psoriasis

China
Peking University

Recruiting

Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Neuroendocrine Neoplasm

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Patients With Mild to Moderate COVID-19

COVID-19

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

IBI110 Combined With Sintilimab in Second-line Advanced or Metastatic Esophageal Squamous Cell Carcinoma(ESCC)

Esophageal Squamous Cell Carcinoma (ESCC) | PD-1 Inhibitors

China
Shenzhen People's Hospital

Recruiting

Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia

Lipid Metabolism Disorders | Familial Hypercholesterolemia - Homozygous | Proprotein Convertase Subtilisin/Kexin 9

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Advanced Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Completed

Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Multicenter, Open-label Extension Study Evaluating the Efficacy and Safety of IBI311 in Subjects With Thyroid Eye Disease

Thyroid Eye Disease, TED

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI129 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of IBI333 in Subjects With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Study of IBI318 in Participants With Advanced Malignancies

Advanced Malignancy

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Advanced Cutaneous Squamous Cell Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

IBI308 in Subjects With Advanced/Metastatic Solid Malignancies

Advanced/Metastatic Solid Malignancies

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in HeFH Patients

Heterozygous Familial Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Unknown

Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization (STOP)

Precancerous Conditions | Oral Cavity Cancer | Mouth Neoplasm

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis

Ulcerative Colitis (UC)

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Subjects With Active Thyroid Eye Disease

Thyroid Eye Disease

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI311 in Healthy Volunteers

Healthy

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

Efficacy and Safety of IBI310 Combined With Sintilimab in Patients With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.

Hypercholesterolemia

China
Shanghai Zhongshan Hospital

Not yet recruiting

A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma
Beijing Tsinghua Chang Gung Hospital

Unknown

Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma | Portal Vein Tumor Thrombosis

China
Tianjin Medical University Cancer Institute and...

Recruiting

HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC

Hepatocellular Carcinoma

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-cluster Differentiation Antigen 47 (CD47) Monoclonal Antibody Injection (IBI188) in Patients With Advanced Malignant Tumors and Lymphomas

Advanced Malignancies

United States
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

MSI-H

China

3

Subscribe